1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 THR B 27 - PRO B 28 MODEL 5 OMEGA =220.40 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION THR B 27 - PRO B 28 MODEL 7 OMEGA =134.22 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION THR B 27 - PRO B 28 MODEL 8 OMEGA =131.54 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION Hua, Q.X. Kochoyan, M. Weiss, M.A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Nature NATUAS 0006 0028-0836 354 238 241 10.1038/354238a0 1961250 Receptor binding redefined by a structural switch in a mutant human insulin. 1991 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2383.698 INSULIN 1 man polymer 3343.831 INSULIN F24G 1 man polymer no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A polypeptide(L) no no FVNQHLCGSHLVEALYLVCGERGGFYTPKT FVNQHLCGSHLVEALYLVCGERGGFYTPKT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens human Homo sample 9606 Homo sapiens repository Initial release Version format compliance Version format compliance 1 0 1994-01-31 1 1 2008-03-24 1 2 2011-07-13 Y 1992-02-28 REL REL 9 1 HAVEL refinement DGII BRUNGER refinement X-PLOR GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B HIS 10 n 10 HIS 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B GLY 24 n 24 GLY 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B PRO 28 n 28 PRO 28 B LYS 29 n 29 LYS 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 6 B B THR PRO 27 28 -139.60 8 B B THR PRO 27 28 134.22 9 B B THR PRO 27 28 131.54 1 B ARG 22 0.317 SIDE CHAIN 2 B ARG 22 0.275 SIDE CHAIN 3 B ARG 22 0.304 SIDE CHAIN 4 B ARG 22 0.317 SIDE CHAIN 5 B ARG 22 0.287 SIDE CHAIN 6 B ARG 22 0.288 SIDE CHAIN 7 B ARG 22 0.320 SIDE CHAIN 8 B ARG 22 0.208 SIDE CHAIN 9 B ARG 22 0.192 SIDE CHAIN 1 -4.41 0.60 121.00 116.59 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 1 3.85 0.60 121.00 124.85 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 1 9.86 1.10 114.20 124.06 A A A CA CB SG CYS CYS CYS 20 20 20 N 1 -5.33 0.60 121.00 115.67 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 1 7.26 0.60 121.00 128.26 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 1 9.61 1.10 114.20 123.81 B B B CA CB SG CYS CYS CYS 19 19 19 N 2 -4.01 0.60 121.00 116.99 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 2 3.75 0.60 121.00 124.75 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 2 -4.96 0.60 121.00 116.04 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 2 5.69 0.60 121.00 126.69 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 2 8.26 1.10 114.20 122.46 B B B CA CB SG CYS CYS CYS 19 19 19 N 3 -4.58 0.60 121.00 116.42 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 3 4.98 0.60 121.00 125.98 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 3 -7.13 0.60 121.00 113.87 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 3 7.44 0.60 121.00 128.44 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 3 6.82 1.10 114.20 121.02 B B B CA CB SG CYS CYS CYS 19 19 19 N 4 -3.76 0.60 121.00 117.24 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 4 4.25 0.60 121.00 125.25 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 4 -4.21 0.60 121.00 116.79 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 4 5.14 0.60 121.00 126.14 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 4 8.07 1.10 114.20 122.27 B B B CA CB SG CYS CYS CYS 19 19 19 N 5 -4.90 0.60 121.00 116.10 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 5 4.21 0.60 121.00 125.21 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 5 12.14 1.10 114.20 126.34 A A A CA CB SG CYS CYS CYS 20 20 20 N 5 -6.38 0.60 121.00 114.62 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 5 7.42 0.60 121.00 128.42 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 5 8.27 1.10 114.20 122.47 B B B CA CB SG CYS CYS CYS 19 19 19 N 6 6.77 1.10 114.20 120.97 A A A CA CB SG CYS CYS CYS 11 11 11 N 6 -4.51 0.60 121.00 116.49 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 6 3.91 0.60 121.00 124.91 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 6 6.67 1.10 114.20 120.87 A A A CA CB SG CYS CYS CYS 20 20 20 N 6 -5.28 0.60 121.00 115.72 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 6 5.90 0.60 121.00 126.90 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 7 -5.15 0.60 121.00 115.85 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 7 5.77 0.60 121.00 126.77 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 8 8.24 1.10 114.20 122.44 A A A CA CB SG CYS CYS CYS 20 20 20 N 8 -4.77 0.60 121.00 116.23 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 8 6.00 0.60 121.00 127.00 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 9 4.04 0.60 121.00 125.04 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 9 -4.00 0.60 121.00 117.00 B B B CB CG CD2 TYR TYR TYR 16 16 16 N 9 4.14 0.60 121.00 125.14 B B B CB CG CD1 TYR TYR TYR 16 16 16 N 1 A SER 9 -128.66 -162.73 1 A CYS 11 -127.45 -165.27 1 A GLN 15 -42.82 -78.33 1 B SER 9 142.49 -59.79 1 B CYS 19 -104.83 43.45 1 B GLU 21 34.42 -146.87 1 B PHE 25 -126.72 -52.29 1 B THR 27 -131.74 -72.35 2 A ILE 2 -23.34 -46.68 2 A VAL 3 -29.96 -46.09 2 A GLU 4 -25.41 -44.82 2 A SER 9 118.15 -162.59 2 A CYS 11 45.33 -162.15 2 A SER 12 -114.84 -162.28 2 A GLN 15 -42.24 -80.95 2 B ASN 3 104.32 169.69 2 B SER 9 112.34 -55.86 2 B ARG 22 91.48 -62.20 2 B PRO 28 -92.46 -81.19 3 A SER 9 -114.86 -159.67 3 A ILE 10 -97.38 -60.64 3 A CYS 11 80.92 -177.70 3 A GLN 15 -60.22 -70.58 3 A LEU 16 -72.38 40.05 3 A CYS 20 -135.00 -54.77 3 B SER 9 110.57 -30.52 3 B CYS 19 -110.13 -79.39 3 B ARG 22 -120.58 -70.87 3 B TYR 26 -18.46 172.70 3 B PRO 28 -61.36 78.28 4 A GLU 4 -93.16 34.82 4 A THR 8 -137.67 -48.52 4 A SER 9 -124.13 -158.74 4 A GLN 15 -56.14 -74.60 4 A LEU 16 -49.82 -17.84 4 A CYS 20 -3.76 -54.46 4 B ASN 3 -115.88 69.72 4 B GLU 21 -15.25 -63.27 4 B TYR 26 -112.42 -168.94 4 B PRO 28 -61.55 90.24 5 A GLU 4 -89.88 44.82 5 A CYS 6 -36.50 -31.80 5 A THR 8 -98.54 59.57 5 A SER 9 120.96 -158.69 5 A SER 12 -116.26 -166.97 5 A TYR 14 -27.44 -61.36 5 A GLN 15 -43.74 -71.77 5 A CYS 20 -125.13 -54.96 5 B ASN 3 99.47 44.08 5 B CYS 7 -119.44 -159.32 5 B SER 9 117.34 -58.95 5 B CYS 19 -109.48 52.97 5 B ARG 22 -116.98 -77.39 5 B PHE 25 -104.45 71.07 6 A GLU 4 -98.78 34.64 6 A SER 9 -124.29 -150.87 6 A CYS 11 89.89 -169.53 6 A SER 12 -118.62 -167.88 6 A GLN 15 -47.89 -71.45 6 A LEU 16 -68.72 12.34 6 A TYR 19 -90.26 58.90 6 B GLU 21 -112.82 75.89 6 B PHE 25 -134.65 -62.84 6 B THR 27 -124.23 -59.55 6 B PRO 28 -9.27 -151.35 7 A ILE 2 -24.61 -49.06 7 A GLU 4 -95.68 44.05 7 A CYS 7 -91.16 -74.31 7 A SER 9 -135.83 -143.05 7 A CYS 11 -121.28 -169.47 7 A SER 12 -115.42 -158.33 7 A CYS 20 -8.21 159.11 7 B SER 9 95.85 -37.80 7 B LEU 11 -47.62 -73.66 7 B ARG 22 -114.92 50.73 7 B PRO 28 -68.36 12.17 8 A ILE 2 -20.97 -49.66 8 A VAL 3 -24.17 -43.17 8 A GLU 4 -24.11 -52.96 8 A SER 9 -128.19 -156.29 8 A CYS 11 -117.91 -161.38 8 A GLN 15 -34.70 -73.67 8 A LEU 16 -64.44 18.68 8 A CYS 20 -107.22 -73.69 8 B ASN 3 137.18 70.02 8 B SER 9 94.24 -40.67 8 B CYS 19 -104.15 40.66 8 B GLU 21 12.78 95.62 9 A VAL 3 -24.28 -43.57 9 A GLU 4 -21.28 -55.57 9 A THR 8 -95.07 56.25 9 A SER 9 120.02 -167.20 9 A CYS 11 -127.22 -160.16 9 A LEU 16 -90.99 47.51 9 B SER 9 109.28 -44.30 9 B LEU 11 -49.13 -75.15 9 B PHE 25 -130.80 -49.89 model building X-PLOR refinement X-PLOR phasing X-PLOR INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY GLY (F24G) (NMR, REPRESENTATIVE PLUS 8 STRUCTURES) Receptor binding redefined by a structural switch in a mutant Human Insulin 1 N N 2 N N A GLU 4 A GLU 4 HELX_P A SER 9 A SER 9 1 1 6 A GLN 15 A GLN 15 HELX_P A TYR 19 A TYR 19 5 2 5 B LEU 11 B LEU 11 HELX_P B CYS 19 B CYS 19 1 3 9 disulf 2.018 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.021 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.022 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 HORMONE HORMONE INS_HUMAN UNP 1 90 P01308 INS_HUMAN UNP 2 25 P01308 90 110 1HIT 1 21 P01308 A 1 1 21 25 54 1HIT 1 30 P01308 B 2 1 30 2 PHE ENGINEERED MUTATION GLY 24 1HIT B P01308 UNP 48 24 1 P 1